




FAST FACTS: SIPONIMOD AND CYP2C9 GENOTYPING

Pre-emptive pharmacogenomic testing has been proven to reduce adverse drug reactions.

Siponimod (Kiendra™) is now registered in South Africa for the treatment of secondary progressive multiple sclerosis (SPMS). Siponimod is contraindicated in patients with the CYP2C9 *3/*3 genotype (poor metabolisers). Dosage adjustment is required for the CYP2C9 *1/*3 and *2/*3 (intermediate metaboliser) genotypes. SPMS patients therefore require CYP2C9 genotyping prior to initiating siponimod therapy.

CYP2C9/Siponimod genotype-based dosing guidelines*



*Source: Siponimod package insert

- CYP2C9 genotyping is now available at Ampath.
- CYP2C9 genotyping is performed as part of our comprehensive pharmacogenomics panel (Test Mnemonic: **PHARMA**).
- Results are available within 10 working days.

For more information please contact: pgx@ampath.co.za

PATHOLOGY SOLUTIONS
ARE IN OUR DNA

ampath.co.za

